---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-077584"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2026-06-25T13:26:59+00:00"
generated_at: "2026-06-25T13:28:11.852694+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CytoSorbents schedules two FDA pre-submission meetings for ticagrelor and DOAC programs in August 2026

## Summary
- Two pre-submission meetings with FDA scheduled for August 2026.
- Meetings will cover CytoSorbents' ticagrelor and DOAC programs.
- Announcement made at 2026 Life Sciences Forum; no financial impact disclosed.

## SEC filing metadata
- accession: 0001104659-26-077584
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2026-06-25T13:26:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000110465926077584/0001104659-26-077584-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000110465926077584/tm2618977d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-077584
- JSON: https://secwatch.observer/filing/0001104659-26-077584.json
- Plain text: https://secwatch.observer/filing/0001104659-26-077584.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.